Governing Cyber Security Risks and Benefits of the Internet of Things: Application to Connected Vehicles and Medical Devices

Creating trust in connectivity including confidentiality, integrity and availability will be key to achieving the promises of the IoT, at least in the automotive and medical sector. Assessing vulnerability, implementing and assessing security controls, designing appropriate standards and regulation as well as insurance and other governance arrangements will be critical elements. But the creation of trust may require that broader societal questions need to be addressed

Governing Cybersecurity Risks and Benefits of the Internet of Things: Connected Medical and Health Devices and Connected Vehicles

IRGC organised in 2016 an expert workshop on 'Governing Cybersecurity Risks and Benefits in the Internet of Things (IoT), applied to connected vehicles and medical devices. In those sectors, connectivity improves both safety and vulnerability, but cybersecurity failures can be life-critical or -threatening. Participants in the workshop acknowledged that dependence on network connected technologies has grown faster than the means to secure it, but that the balancing of risk and benefit is very complex

Workshop Report: The Economics of Precision Medicine

This report from a multi-stakeholder workshop on the ‘Economics of precision medicine’ addresses the issues of cost-effectiveness, as well as the need to revise how economic and social value can be valorised and financed, and to develop new business models for fundamentally personalised gene therapies with high up-front costs

Risk governance: An Overview of Drivers and Success Factors

This paper proposes a broad review of what risk governance is about and the main deficits that often hinder effective governance of complex, uncertain or systemic risks. Working to overcome identified roadblocks to effective disaster risk management is a first way to go. This paper proposes and discusses some of the drivers and hallmarks of success, focusing on how countries and organisations organise internally to deal with risk

IRGC Guidelines for the Governance of Systemic Risks

IRGC’s guidelines for the governance of systemic risks addresses the question of how to deal with systemic risks in the context of system transitions, i.e., in situations that require adaptation to new context conditions or transformation of an organisation or ecosystem. The guidelines comprise seven interlinked steps. The guidelines successful implementation depends on strong leadership and the willingness to adapt or revise processes, focus on mid- and long-term issues, and accept and resolve trade-offs

IRGC Resource guide on Resilience

An edited collection of authored pieces comparing, contrasting, and integrating risk and resilience with an emphasis on ways to measure resilienc

Collection, Access and Use of Human Genetic Information for Precision Medicines: Risk Governance Considerations

Gene technologies and their application by industry are developing rapidly, particularly in the US and in China. Yet, governance of the field of genomic for precision medicine is developing more slowly and needs to catch up. The rapid developments in science and technology but also in how cultures and values consider questions of ethics, privacy and data protection, pose challenges to regulators and policymakers. This report summarises some of the discussions at a workshop in August 2015

IRGC Guidelines for Emerging Risk Governance: Guidance for the Governance of Unfamiliar Risks

The IRGC Guidelines for Emerging Risk Governance describe key steps and associated methodologies for early identification and management of emerging risks. The process proposed in this report covers an overarching, flexible and adaptable set of guidelines designed to deal with complex, evolving and uncertain environments

A Roadmap for the Development of Precision Medicine

The purpose of the roadmap proposed by IRGC is to recommend a structured process that organisations can follow in their transition towards the development of precision medicine. The process is adaptable, and each organisation should further develop it to align with its own needs, culture and objectives. The roadmap suggests a comprehensive approach to the development of precision medicine: it begins with the creation of a space for dialogue among stakeholders, it considers a step-wise implementation of precision medicine, it recommends a careful attention to the data issue, and it reminds that regulation and payment systems will have to be adapted